Press "Enter" to skip to content

Biologics Offer Equal Benefit For Young-Onset And Elderly-Onset RA Patients

The biologic disease-modifying antirheumatic drugs offer identical health benefits for rheumatoid arthritis (RA) patients of all age groups, a recent study highlighted. In this study, individuals infected with RA in the earlier stages of their lives and those infected in their older life stage were offered similar biologic disease-modifying antirheumatic drugs. The results of this research showed that both the patients’ groups offered alike health progress in clinical disease at 48 Weeks following the use of biologic disease-modifying antirheumatic drugs. Moreover, both the groups showed alike adverse events discontinuation rates and drug maintenance.

The Lead Author of the study Dr. Sadao Jinno stated, “Individuals with elderly-onset RA might present increased disease activities and higher disabilities when compared to those with young-onset RA. In spite of this, earlier researches demonstrated elderly patients get biologics less often than younger patients. This highlights that individuals with elderly-onset RA are strongly undertreated. Conversely, in our regular practice, we have observed that numerous elderly-onset RA individuals were offered treatment with biologics securely and efficiently. We wanted to study if there are variations in the safety and effectiveness of biologics between the two age groups.” The study included 7,183 participants with RA with the age group of 18 or older.

Dr. Jinno stated, “The latest study’s outcomes demonstrated that there were no noteworthy dissimilarities in Clinical Disease Activity Index scores at 48 Weeks between young-onset and elderly-onset RA. This signifies that biologics can be employed for both patients with elderly-onset RA and young-onset RA efficiently. We also discovered there was no dissimilarity in unfavorable event discontinuation rates between both groups.

On a similar note, a recent study stated that the use of ultrasound data cannot help in deciding an efficient treatment plan for patients with early RA onset. In this study, no additional decrease in structural damage or MRI inflammation was noted as compared to the traditional treat-to-target treatment plans.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *